Page 70 - 2020_11-Haematologica-web

M. Gooptu and J. Koreth
tributes to the success of unrelated donor marrow transplantation. Blood. 2007;110 (13):4576-4583.
16. Verneris MR, Lee SJ, Ahn KW, et al. HLA mismatch is associated with worse out- comes after unrelated donor reduced-inten- sity conditioning hematopoietic cell trans- plantation: an analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(10):1783-1789.
17. Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophos- phamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus- host disease with haemopoietic cell trans- plantation with reduced-intensity condition- ing: a randomised phase 2 trial with a non- randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132-e143.
18. Nykolyszyn C, Granata A, Pagliardini T, et al. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD pro- phylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(2):349- 355.
19. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell com- pared with bone marrow transplantation in the management of hematologic malignan- cies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074-5087.
20. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone mar- row from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
21.Chen Y-B, Wang T, Hemmer MT, et al. GVHD after umbilical cord blood transplan- tation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant 2017;52(3):400-408.
22. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft- versus-host disease after marrow transplan- tation from unrelated donors. Blood. 2000;96(6):2062-2068.
23. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrex- ate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-ver- sus-host disease prophylaxis after HLA- identical sibling bone marrow transplanta- tion. Blood. 1998;92(7):2303-2314.
24. Bacigalupo A. ATG in allogeneic stem cell transplantation: standard of care in 2017? Point. Blood Adv. 2017;1(9):569-572.
25. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unre- lated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947.
26. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft- versus-host disease, chronic lung dysfunc- tion, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor trans- plantation. Biol Blood Marrow Transplant. 2006;12(5):560-565.
27. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophy- laxis with or without anti-T-cell globulin in
haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
28.Socié G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-ver- sus-host disease prophylaxis with or with- out anti–T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-6382.
29.Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43-53.
30.Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft- versus-host disease–free survival in patients undergoing HLA-matched unrelated mye- loablative hematopoietic cell transplanta- tion. J Clin Oncol. 2017;35(36):4003-4011.
31. Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft- vs-host disease and high likelihood of post- transplant lymphoproliferative disorder. Biol Blood Marrow Transplant. 2010;16(7):915- 926.
32. Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globu- lin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacody- namic cohort analysis. Lancet Haematol. 2017;4(4):e183-e191.
33. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplan- tation for hematologic malignancies using nonmyeloablative conditioning and high- dose, posttransplantation cyclophos- phamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
34. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide pre- vents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppres- sion. J Clin Invest. 2019;129(6):2357-2373.
35. De Jong CN, Meijer E, Bakunina K, et al. Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors. Blood. 2019;134(Suppl 1):1.
36. Slavik JM, Lim DG, Burakoff SJ, Hafler DA. Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant prolifera- tion of human CD8(+) T lymphocytes. J Immunol. 2001;166(5):3201-3209.
37. Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
38.Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophy- laxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372-1377.
39. Armand P, Kim HT, Sainvil M-M, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173(1):96-104.
40. Sandmaier BM, Kornblit B, Storer BE, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil- based graft-versus-host disease prophylaxis
for patients after unrelated non-myeloabla- tive haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019;6(8):e409-e418.
41. Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host dis- ease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937-947.
42.Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allo- geneic stem cell transplantation. Blood. 2008;112(12):4425-4431.
43.Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):551-557.
44. Solomon SR, Sanacore M, Zhang X, et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplanta- tion cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014;20 (11):1828-1834.
45. Gooptu M, Kim HT, Howard A, et al. Effect of sirolimus on immune reconstitution fol- lowing myeloablative allogeneic stem cell transplantation: an ancillary analysis of a randomized controlled trial comparing tacrolimus/sirolimus and tacrolimus/methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019;25(11):2143-2151.
46. Tkachev V, Furlan SN, Watkins B, et al. Combined OX40L and mTOR blockade controls effector T cell activation while pre- serving Treg reconstitution after transplant. Sci Transl Med. 2017;9(408):eaan3085.
47. Reinherz EL, Geha R, Rappeport JM, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype- mismatched bone marrow for severe com- bined immunodeficiency. Proc Natl Acad Sci U S A. 1982;79(19):6047-6051.
48.Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lym- phocytes from donor bone marrow. J Clin Oncol. 1992;10(7):1191-1200.
49.Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated mar- row transplantation for chronic myeloge- nous leukemia. Blood. 1994;83(7):1980- 1987.
50. Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA- identical siblings: advantage of T-cell anti- bodies with narrow specificities. Blood. 2000;95(12):3996-4003.
51. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effec- tive prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78(8):2139-2149.
52. Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone mar- row by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988;72(4):1168-1176.
53. Wagner JE, Thompson JS, Carter SL, Kernan NA, Unrelated donor marrow transplanta- tion trial. Effect of graft-versus-host disease
2558
haematologica | 2020; 105(11)